EUVIMEDEUVIMED entdecken
Crossref

Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma

Bihui Cao iD, Qianqian Ni, Zhuxin Chen, Shuo Yang, Xinkui Zhang, Haotao Su, Zhenfeng Zhang, Qi Zhao iD, Xiaolan Zhu, Manting Liu

Journal of Leukocyte Biology · 13.02.2025 · 117 (2)

DOI: 10.1093/jleuko/qiae144 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 26.06.2024. Verfasst von Bihui Cao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Sou…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms, Killer Cells, Natural. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Guangzhou Science and Technology Project, Plan on Enhancing Scientific Research in GMU, Science and Technology Development Fund of Macau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a highly malignant tumor characterized by insidious onset and rapid progression, with limited treatment choices. One treatment modality, chimeric antigen receptor (CAR)-modified natural killer (NK) cell immunotherapy, has shown promise for various cancers. However, the treatment efficacy of CAR-NK cells for HCC remain inferior. In this study, we developed two glypican-3 (GPC3)-specific CAR-NK-92 cell lines (GPC3-CAR-NK) and explored their antitumor efficacy for the treatment of HCC. Significant levels of cytokine production and in vitro cytotoxicity were produced following co-culture of GPC3+ HCC cells with the developed GPC3-CAR-NK cells. GC33-G2D-NK cells with NK cell-specific signaling domains showed better activation and killing abilities than GC33-CD28-NK cells containing T-cell-specific signaling domains. Moreover, GC33-G2D-NK cells efficiently eliminated tumors in cell-derived xenograft and patient-derived xenograft mouse models. In an abdominal metastasis model, intraperitoneally delivered GC33-G2D-NK cells showed better antitumor ability than intravenously injected cells. Finally, the combination of microwave ablation (MWA) with GC33-G2D-NK cell administration showed greater CAR-NK infiltration and tumor regression in ablated tumors than monotherapy alone. These findings indicate that administration of GPC3-CAR-NK cells may be a potential strategy for the treatment of HCC, and regional delivery or their combination with MWA may optimize their efficacy against HCC and may have translational value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularGlypicansLiver NeoplasmsKiller Cells, NaturalReceptors, Chimeric AntigenImmunotherapy, AdoptiveAnimalsHumansXenograft Model Antitumor AssaysMiceCell Line, Tumor

Stichwörter der Autor:innen

HCCMWAchimeric antigen receptorglypican-3natural killer

Substanzen

GlypicansReceptors, Chimeric AntigenGPC3 protein, human

Autor:innen und Institutionen

  • Department of Cardiac Surgery, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510080, China.
  • Department of Guangdong Provincial Key Laboratory of Pathogenesis and Precision Prevention of Heart Disease, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou 510100, China.
  • Department of Radiology, Central Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore.
  • Department of Guangdong Provincial and Guangzhou Municipal Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China.
  • Faculty of Health Sciences, MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China.

ORCID-Profile: Bihui Cao, Qi Zhao

Förderung

  • Guangzhou Science and Technology Project
  • Plan on Enhancing Scientific Research in GMU
  • Science and Technology Development Fund of Macau
  • University of Macau
  • National Natural Science Foundation of China

Zitieren

APA

Cao, B., Ni, Q., Chen, Z., Yang, S., Zhang, X., Su, H., Zhang, Z., Zhao, Q., Zhu, X., & Liu, M. (2025). Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma. Journal of Leukocyte Biology, 117(2). https://doi.org/10.1093/jleuko/qiae144

Vancouver

Cao B, Ni Q, Chen Z, Yang S, Zhang X, Su H, et al. Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma. Journal of Leukocyte Biology. 2025;117(2). doi:10.1093/jleuko/qiae144

BibTeX
@article{Cao2025,
  author = {Cao, Bihui and Ni, Qianqian and Chen, Zhuxin and Yang, Shuo and Zhang, Xinkui and Su, Haotao and Zhang, Zhenfeng and Zhao, Qi and Zhu, Xiaolan and Liu, Manting},
  title = {Development of glypican-3-specific chimeric antigen receptor-modified natural killer cells and optimization as a therapy for hepatocellular carcinoma},
  journal = {Journal of Leukocyte Biology},
  year = {2025},
  volume = {117},
  number = {2},
  doi = {10.1093/jleuko/qiae144}
}
Kostenlos starten →